Unterehmen auf Watchlist setzen
Encompass Health
ISIN: US29261A1007
WKN: A2H9HM
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Encompass Health · ISIN: US29261A1007 · PR Newswire (ID: 20240724CL68603)
24 Juli 2024 02:27PM

Encompass Health increases and declares dividend on common stock and announces increase in common stock repurchase authorization


BIRMINGHAM, Ala., July 24, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE:EHC) today announced that its board of directors approved an increase in the Company's quarterly dividend of approximately 13% and declared a quarterly cash dividend on its common stock of $0.17 per share, payable on Oct. 15, 2024, to holders of record on Oct. 1, 2024.

Encompass Health also announced its board approved resetting the aggregate common stock repurchase authorization to $500 million. The Company repurchased approximately $17 million of its common stock during the second quarter and had approximately $181 million remaining under the prior authorization as of June 30, 2024.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 163 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Becker's Hospital Review's 150 Top Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Forward-Looking Statements

Statements contained in this press release which are not historical facts, such as the timing and amounts of dividends and common stock repurchases, are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking statements speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking statements, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the legal, regulatory and administrative developments that occur at the federal, state and local levels; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; Encompass Health's ability to comply with extensive, complex, and ever-changing regulations in the healthcare industry; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; the price of our common stock which could adversely affect our willingness and ability to repurchase common stock, and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10K for the year ended December 31, 2023, and Form 10-Q for the quarter ended Mar. 31, 2024.

Media Contact:

Polly Manuel | 205-970-5912

polly.manuel@encompasshealth.com

Investor Relations Contact:

Mark Miller | 205-970-5860

mark.miller@encompasshealth.com   

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/encompass-health-increases-and-declares-dividend-on-common-stock-and-announces-increase-in-common-stock-repurchase-authorization-302205321.html

SOURCE Encompass Health Corp.

Visuelle Wertentwicklung / Kursverlauf · Encompass Health
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942